Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorHe Eye Hospital
About this trial
The prevalence of refractive ametropia is rising year by year. Refractive surgery has become the main approach for adults to correct refractive ametropia, and postoperative complications have aroused extensive attention from clinicians. Dry eye after refractive surgery is one of the postoperative complications, which is an important cause of affecting the postoperative visual quality and satisfaction of patients. It was reported that 3% diquafosol (DQS) and 0.1% hyaluronic acid (HA) can relieve dry eye symptoms. This study aims to compare the efficacy of 3% DQS and 0.1% HA in treating dry eye after Trans-PRK
Eligibility criteria
Qualifiers
Age 18-40 years.
The refractive status should be maintained at least for more than 2 years, during which the annual increase in myopia should be controlled within 0.50 D.
Pherical equivalent (SE) ≤-6.00D, astigmatic power≤-2.00D.
Best corrected vision before surgery≥1.0.
Disqualifiers
Suspected of having keratoconus, a definite diagnosis of keratoconus, or another type of corneal dilatation disease.
There is active inflammation or symptoms of infection in the eye.
The thickness of the cornea does not meet the preset cutting depth requirement: the thickness of the central cornea should be greater than 450 μm, and the thickness of the central corneal stroma remaining under the corneal flap should be maintained above 250 μm after the intended cutting (280 μm recommended).
Dry eye.
Trial design
Treatments tested in this trial
- 3% Diquafosol Sodium Eye Drops
- 0.1% hyaluronic acid
Treatment groups
76 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov